Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 14, 2006; 12(42): 6766-6770
Published online Nov 14, 2006. doi: 10.3748/wjg.v12.i42.6766
Published online Nov 14, 2006. doi: 10.3748/wjg.v12.i42.6766
Figure 1 Metabolism of atofluding to into TFU and 5-FU.
The acetyl group on the N1 position of atofluding was hydrolyzed in the presence of H2O into TFU rapidly due to the influence of fluorine on the C5 position. 5-FU was transformed from TFU slowly and continually by the liver microsomal enzymes.
Figure 2 TFU inhibits MKN-45 (A) and SGC-7901 (B) cell growth in vitro.
Cells were treated with TFU (0.1, 1, 10, 100, 1000 μg/mL) for up to 120 h. Viable cell numbers were evaluated by the MTT assay and expressed as percentage of untreated controls at the concurrent time point. The bars indicate means ± SD (n = 3).
- Citation: Liu J, Xu WF, Cui SX, Zhou Y, Yuan YX, Chen MH, Wang RH, Gai RY, Makuuchi M, Tang W, Qu XJ. Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil. World J Gastroenterol 2006; 12(42): 6766-6770
- URL: https://www.wjgnet.com/1007-9327/full/v12/i42/6766.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i42.6766